Eli Lilly and Company (SWX:LLY)
580.00
0.00 (0.00%)
At close: Sep 30, 2025
Eli Lilly and Company Revenue
Eli Lilly and Company had revenue of $15.56B USD in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly and Company had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
12.27
Revenue / Employee
$1.13M
Employees
47,000
Market Cap
519.75B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Eli Lilly and Company News
- 1 day ago - Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth - Seeking Alpha
- 1 day ago - LLY Stock Set For A 20% Breakout? - Forbes
- 1 day ago - Novo, Lilly Weight-Loss Drugs May Help Alzheimer's Patients. What It Means for the Stocks. - Barrons
- 4 days ago - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff - Seeking Alpha
- 4 days ago - Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem - PRNewsWire
- 4 days ago - Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why. - Barrons
- 5 days ago - Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease - PRNewsWire
- 5 days ago - US FDA approves Eli Lilly's therapy for metastatic breast cancer - Reuters